Neurofeedback for Bulimia
Trial Summary
What is the purpose of this trial?
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using a wearable brain imaging device, functional near-infrared spectroscopy (fNIRS). The investigators will examine how this training may influence inhibitory control and BN symptoms.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but ongoing medical treatment that may interfere with the study could exclude you from participating.
What data supports the effectiveness of the treatment Real fNIRS Neurofeedback and Sham-Control fNIRS Neurofeedback for Bulimia?
Research on similar treatments, like EEG neurofeedback, shows promise in reducing binge-eating episodes and improving decision-making in people with binge-eating disorder. Additionally, fNIRS neurofeedback has been shown to help regulate brain activity and improve symptoms in other conditions, suggesting potential benefits for eating disorders.12345
Is neurofeedback using fNIRS safe for humans?
Functional near-infrared spectroscopy (fNIRS) neurofeedback is generally considered safe for humans, as it is noninvasive and has been used in various studies without major safety concerns. It has been applied in healthy individuals and clinical populations, such as those with ADHD and autism, showing potential for modulating brain activity without reported adverse effects.14567
How does Real fNIRS Neurofeedback treatment for Bulimia differ from other treatments?
Real fNIRS Neurofeedback is unique because it uses real-time feedback to help patients regulate their brain activity, which is not a common approach in traditional bulimia treatments. This method focuses on directly modifying brain patterns associated with eating behaviors, offering a novel way to address the neurocognitive roots of the disorder.34589
Research Team
Laura A Berner, Ph.D.
Principal Investigator
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
This trial is for women aged 18 to 35 who have been diagnosed with bulimia nervosa and are within a certain weight range for their height. They must speak English but cannot be pregnant, planning pregnancy, or breastfeeding during the study. Those with allergies to meal ingredients, in specific psychotherapy, or with major medical conditions that could affect the study can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Psychodiagnostic assessment and one in-person evaluation
Neurofeedback Session
Participants undergo either real or sham-control neurofeedback during eating
Follow-up
Participants complete behavioral tasks and online questionnaires before and after the neurofeedback session, including a remote follow-up assessment
Treatment Details
Interventions
- Real fNIRS Neurofeedback
- Sham-Control fNIRS Neurofeedback
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor